Journal
BIOACTIVE MATERIALS
Volume 6, Issue 12, Pages 4707-4716Publisher
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2021.05.010
Keywords
Nasopharyngeal carcinoma (NPC); Chemoradiotherapy; Polymeric nanoparticles; Precise treatment
Funding
- Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars [2020B1515020027]
- Guangzhou Science and Technology Bureau [202002020070, 202102010181, 202102010007]
- Fundamental Research Funds for the Central Universities [19ykpy108, 20ykpy93]
- Guangdong Science and Technology Department [2020B1212060018, 2020B1212030004]
- Shenzhen Key Medical Discipline Construction Fund [SZXK039]
- Guangdong Basic and Applied Basic Research Fund Foundation [2019A1515110204, 2020A1515010523]
- Yat-sen Scientific Research Project [YXQH202018]
- Shenzhen Innovation of Science and Technology Commission [LGKCYLWS2020089]
- National Key R&D Program of China [2017YFE0102400]
- Shenzhen Science and Technology Program [JCYJ20190807160401657]
Ask authors/readers for more resources
By developing RGD-targeted platinum-based nanoparticles, targeted chemoradiotherapy for NPC can be achieved with improved delivery efficiency of cisplatin. RPNs act as radiotherapy sensitizer and chemotherapy agents, leading to remarkable therapeutic outcome in synergistic chemoradiotherapy for NPC.
Despite extensive use of radiotherapy in nasopharyngeal carcinoma (NPC) treatment because of its high radiosensitivity, there have been huge challenges in further improving therapeutic effect, meanwhile obviously reducing radiation damage. To this end, synergistic chemoradiotherapy has emerged as a potential strategy for highly effective NPC therapy. Here, we developed RGD-targeted platinum-based nanoparticles (RGD-PtNPs, denoted as RPNs) to achieve targeted chemoradiotherapy for NPC. Such nanoparticles consist of an RGDconjugated shell and a cis-platinum (CDDP) crosslinking core. Taking advantage of RGD, the RPNs may effectively accumulate in tumor, penetrate into tumor tissues and be taken by cancer cells, giving rise to a high delivery efficiency of CDDP. When they are fully enriched in tumor sites, the CDDP loaded RPNs can act as radiotherapy sensitizer and chemotherapy agents. By means of X-ray-promoted tumor cell uptake of nanoparticle and CDDP-induced cell cycle arrest in radiation-sensitive G2/M phases, RPNs may offer remarkable therapeutic outcome in the synergistic chemoradiotherapy for NPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available